Table 1 Demographics and clinicopathological parameters (n = 1023)
Variables | N = 1023 | Rate (%) |
|---|---|---|
Demography | Age (mean ± SD) | 64.14 ± 7.12 |
Male: % (n/n) | 59.2 (605/1023) | |
Female: % (n/n) | 40.9 (418/1023) | |
ASA-score | ASA-1: % (n/n) | 70.0 (716/1023) |
ASA-2: % (n/n) | 26.9 (275/1023) | |
ASA-3: % (n/n) | 3.1 (32/1023) | |
Comorbidity | Hypertension: % (n/n) | 20.8 (213/1023) |
Diabetes: % (n/n) | 6.6 (68/1023) | |
COPD: % (n/n) | 1.3 (13/1023) | |
Liver cirrhosis: % (n/n) | 0.7 (7/1023) | |
Coronary artery disease:% (n/n) | 2.5 (26/1023) | |
Location of lesion | Upper third: % (n/n) | 23.2 (238/1023) |
Middle third: % (n/n) | 65.7 (672/1023) | |
Lower third: % (n/n) | 11.0 (113/1023) | |
Histological type | Squamous carcinoma: % (n/n) | 97.8 (1000/1023) |
Adenocarcinoma: % (n/n) | 0.4 (4/1023) | |
Small cell carcinoma: % (n/n) | 1.5 (15/1023) | |
Sarcocarcinoma: % (n/n) | 0.4 (4/1023) | |
Tumor size |  ≤ 3 cm: % (n/n) | 40.1 (410/1023) |
3–5 cm: % (n/n) | 35.1 (359/1023) | |
 ≥ 5 cm: % (n/n) | 24.8 (254/1023) | |
Surgery-alone | n (%) | 91.1 (932/1023) |
Pathological T stage (%) | Tis∼1: % (n/n) | 23.6 (220/932) |
T2: % (n/n) | 22.5 (210/932) | |
T3: % (n/n) | 44.9 (418/932) | |
T4: % (n/n) | 9.0 (84/932) | |
Pathological N stage (%) | N0: % (n/n) | 61.3 (571/932) |
N1: % (n/n) | 24.9 (232/932) | |
N2: % (n/n) | 10.8 (101/932) | |
N3: % (n/n) | 3.0 (28/932) | |
Pathological TNM stage (%) | I0-IB: % (n/n) | 21.4 (199/932) |
IIA: % (n/n) | 16.5 (154/932) | |
IIB: % (n/n) | 21.6 (201/932) | |
IIIA: % (n/n) | 6.3 (59/932) | |
IIIB: % (n/n) | 27.7 (258/932) | |
IVA: % (n/n) | 6.5 (61/932) | |
Neoadjuvant chemotherapy with surgery | % (n/n) | 8.9 (91/1023) |
cIIIB: % (n/n) | 70.3 (64/91) | |
cIVA: % (n/n) | 29.7 (27/91) | |
Thoracoscopy combined with laparotomy | % (n/n) | 78.6 (804/1023) |
Thoracoscopy combined with laparoscopy | % (n/n) | 21.4 (219/1023) |